Efficacy and Safety of 2 Fingolimod Doses vs Glatiramer Acetate for the Treatment of Patients With Relapsing-Remitting Multiple Sclerosis
Sign Up to like & getrecommendations! Published in 2020 at "JAMA Neurology"
DOI: 10.1001/jamaneurol.2020.2950
Abstract: Key Points Question Is treatment with a fingolimod dose of 0.5 mg or 0.25 mg superior to glatiramer acetate, 20 mg, in reducing relapse activity over 12 months in adult participants aged 18 to 65… read more here.
Keywords: relapsing remitting; treatment; fingolimod; multiple sclerosis ... See more keywords
Skeletonized mean diffusivity and neuropsychological performance in relapsing‐remitting multiple sclerosis
Sign Up to like & getrecommendations! Published in 2022 at "Brain and Behavior"
DOI: 10.1002/brb3.2591
Abstract: Peak width of Skeletonized Mean Diffusivity (PSMD), as a novel marker of white matter (WM) microstructure damage, is associated with cognitive decline in several WM pathologies (i.e., small vessel disorders). We hypothesized that markers combining… read more here.
Keywords: relapsing remitting; remitting multiple; skeletonized mean; mean diffusivity ... See more keywords
Sexual dysfunction in female patients with relapsing‐remitting multiple sclerosis
Sign Up to like & getrecommendations! Published in 2017 at "Brain and Behavior"
DOI: 10.1002/brb3.699
Abstract: Sexual dysfunction (SD) is one of the common symptoms of multiple sclerosis (MS) and is often underdiagnosed, especially in women. Relapsing‐remitting multiple sclerosis (RRMS) is the most widespread form of the disease, but the data… read more here.
Keywords: sclerosis; female patients; sexual dysfunction; relapsing remitting ... See more keywords
Unraveling the MRI‐Based Microstructural Signatures Behind Primary Progressive and Relapsing–Remitting Multiple Sclerosis Phenotypes
Sign Up to like & getrecommendations! Published in 2021 at "Journal of Magnetic Resonance Imaging"
DOI: 10.1002/jmri.27806
Abstract: The mechanisms driving primary progressive and relapsing–remitting multiple sclerosis (PPMS/RRMS) phenotypes are unknown. Magnetic resonance imaging (MRI) studies support the involvement of gray matter (GM) in the degeneration, highlighting its damage as an early feature… read more here.
Keywords: progressive relapsing; primary progressive; relapsing remitting; remitting multiple ... See more keywords
Multimodal magnetic resonance imaging quantification of gray matter alterations in relapsing-remitting multiple sclerosis and neuromyelitis optica spectrum disorder.
Sign Up to like & getrecommendations! Published in 2022 at "Journal of neuroscience research"
DOI: 10.1002/jnr.25035
Abstract: Herein, we combined neurite orientation dispersion and density imaging (NODDI) and synthetic magnetic resonance imaging (SyMRI) to evaluate the spatial distribution and extent of gray matter (GM) microstructural alterations in patients with relapsing-remitting multiple sclerosis… read more here.
Keywords: gray matter; resonance imaging; magnetic resonance; relapsing remitting ... See more keywords
[Cladribine tablets : Oral immunotherapy of relapsing-remitting multiple sclerosis with short yearly treatment periods].
Sign Up to like & getrecommendations! Published in 2018 at "Der Nervenarzt"
DOI: 10.1007/s00115-018-0498-0
Abstract: BACKGROUND The selective modulation of lymphocyte numbers and function is an attractive concept in the treatment of relapsing-remitting multiple sclerosis (RMS). OBJECTIVE Cladribine tablets (Mavenclad®), an oral RMS medication with an innovative treatment concept, have… read more here.
Keywords: relapsing remitting; treatment; cladribine tablets; disease activity ... See more keywords
TSPO PET with [18F]GE-180 sensitively detects focal neuroinflammation in patients with relapsing–remitting multiple sclerosis
Sign Up to like & getrecommendations! Published in 2018 at "European Journal of Nuclear Medicine and Molecular Imaging"
DOI: 10.1007/s00259-018-3974-7
Abstract: PurposeExpression of the translocator protein (TSPO) is upregulated in activated macrophages/microglia and is considered to be a marker of neuroinflammation. We investigated the novel TSPO ligand [18F]GE-180 in patients with relapsing–remitting multiple sclerosis (RRMS) to… read more here.
Keywords: tspo; pet; relapsing remitting; 18f 180 ... See more keywords
Acute posterior multifocal placoid pigment epitheliopathy after alemtuzumab treatment for relapsing–remitting multiple sclerosis
Sign Up to like & getrecommendations! Published in 2019 at "Journal of Neurology"
DOI: 10.1007/s00415-019-09288-y
Abstract: Alemtuzumab, a monoclonal antibody against CD52, is a highly effective treatment of relapsing–remitting multiple sclerosis (RRMS), but it is known to cause secondary autoimmunity in 40% of patients [1]. We present a case of a… read more here.
Keywords: relapsing remitting; treatment; treatment relapsing; alemtuzumab ... See more keywords
Real-world outcomes of teriflunomide in relapsing–remitting multiple sclerosis: a prospective cohort study
Sign Up to like & getrecommendations! Published in 2022 at "Journal of Neurology"
DOI: 10.1007/s00415-022-11118-7
Abstract: To explore efficacy, risk factors, safety, and persistence of teriflunomide in relapsing–remitting multiple sclerosis (RRMS) cohort. This prospective, observational cohort study included 217 consecutive teriflunomide treated RRMS patients, 192 of which with at least 3-month… read more here.
Keywords: treatment; remitting multiple; multiple sclerosis; teriflunomide relapsing ... See more keywords
Early putamen hypertrophy and ongoing hippocampus atrophy predict cognitive performance in the first ten years of relapsing-remitting multiple sclerosis
Sign Up to like & getrecommendations! Published in 2020 at "Neurological Sciences"
DOI: 10.1007/s10072-020-04395-5
Abstract: Background The first years of relapsing-remitting multiple sclerosis (RRMS) constitute the most vulnerable phase for the progression of cognitive impairment (CImp), due to a gradual decrease of compensatory mechanisms. In the first 10 years of RRMS,… read more here.
Keywords: hippocampus; volume; relapsing remitting; years relapsing ... See more keywords
REALMS study: real-world effectiveness and safety of fingolimod in patients with relapsing-remitting multiple sclerosis in Portugal
Sign Up to like & getrecommendations! Published in 2020 at "Neurological Sciences"
DOI: 10.1007/s10072-020-04726-6
Abstract: Fingolimod, an oral sphingosine 1-phosphate receptor modulator, is approved by EMA for relapsing-remitting multiple sclerosis (RRMS). To assess the effectiveness and safety of fingolimod in patients with RRMS in real-world clinical practice in Portugal. Retrospective,… read more here.
Keywords: effectiveness safety; relapsing remitting; safety; fingolimod ... See more keywords